IL145346A - Dimeric compounds and their use as inhibitors of neuraminidase - Google Patents

Dimeric compounds and their use as inhibitors of neuraminidase

Info

Publication number
IL145346A
IL145346A IL14534600A IL14534600A IL145346A IL 145346 A IL145346 A IL 145346A IL 14534600 A IL14534600 A IL 14534600A IL 14534600 A IL14534600 A IL 14534600A IL 145346 A IL145346 A IL 145346A
Authority
IL
Israel
Prior art keywords
neuraminidase
inhibitors
dimeric compounds
dimeric
compounds
Prior art date
Application number
IL14534600A
Other languages
English (en)
Other versions
IL145346A0 (en
Original Assignee
Biota Scient Management
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biota Scient Management filed Critical Biota Scient Management
Publication of IL145346A0 publication Critical patent/IL145346A0/xx
Publication of IL145346A publication Critical patent/IL145346A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
IL14534600A 1999-03-12 2000-03-09 Dimeric compounds and their use as inhibitors of neuraminidase IL145346A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP9139A AUPP913999A0 (en) 1999-03-12 1999-03-12 Novel chemical compounds and their use
PCT/AU2000/000165 WO2000055149A1 (en) 1999-03-12 2000-03-09 Dimeric compounds and as inhibitors of neuraminidase

Publications (2)

Publication Number Publication Date
IL145346A0 IL145346A0 (en) 2002-06-30
IL145346A true IL145346A (en) 2005-11-20

Family

ID=3813338

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14534600A IL145346A (en) 1999-03-12 2000-03-09 Dimeric compounds and their use as inhibitors of neuraminidase

Country Status (26)

Country Link
US (1) US6548476B1 (xx)
EP (1) EP1165541B1 (xx)
JP (1) JP5160000B2 (xx)
KR (1) KR100805906B1 (xx)
CN (1) CN1343205A (xx)
AP (1) AP2001002277A0 (xx)
AT (1) ATE295361T1 (xx)
AU (2) AUPP913999A0 (xx)
BR (1) BR0008939A (xx)
CA (1) CA2367755C (xx)
CZ (1) CZ20013274A3 (xx)
DE (1) DE60020100T2 (xx)
EA (1) EA200100968A1 (xx)
ES (1) ES2241581T3 (xx)
HK (1) HK1041693B (xx)
HU (1) HUP0200190A3 (xx)
ID (1) ID29868A (xx)
IL (1) IL145346A (xx)
MX (1) MXPA01009203A (xx)
NO (1) NO327812B1 (xx)
NZ (1) NZ514041A (xx)
PL (1) PL350228A1 (xx)
TR (1) TR200102794T2 (xx)
TW (1) TWI268279B (xx)
WO (1) WO2000055149A1 (xx)
ZA (1) ZA200107450B (xx)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA001603B1 (ru) * 1996-11-14 2001-06-25 Байота Сайентифик Менеджмент Пти Лтд. Новые соединения и методы их применения
DE19930177B4 (de) 1999-06-30 2007-02-08 Nikolai Vladimirovich Bovin Intermolekular assoziierende Verbindungen und deren Verwendung
AUPQ288499A0 (en) 1999-09-16 1999-10-07 Biota Scientific Management Pty Ltd Antiviral agents
AUPR001000A0 (en) 2000-09-08 2000-10-05 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AUPR879501A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
KR100942492B1 (ko) 2001-11-09 2010-02-12 비오타 사이언티픽 매니지먼트 피티와이 엘티디 이량체 화합물 및 항바이러스제로서의 그의 용도
AU2002340632B2 (en) * 2001-11-09 2008-03-20 Biota Scientific Management Pty Ltd Dimeric compounds and their use as anti-viral agents
AU2002336823B2 (en) * 2001-11-09 2008-03-20 Biota Scientific Management Pty Ltd Dimeric compounds and their use as anti-viral agents
AUPR879601A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AUPR879701A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AUPR879401A0 (en) 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AU2002340635B2 (en) * 2001-11-09 2008-03-13 Biota Scientific Management Pty Ltd Dimeric compounds and their use as anti-viral agents
EP2402036B1 (en) 2002-09-06 2018-02-14 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently attached thereto
US7576235B2 (en) 2004-12-04 2009-08-18 Xerox Corporation Processes for preparing bis(urea-urethane) compounds
US7153349B2 (en) 2004-12-04 2006-12-26 Xerox Corporation Phase change inks containing curable trans-1,2-cyclohexane bis(urea-urethane) compounds
US7317122B2 (en) 2004-12-04 2008-01-08 Xerox Corporation Curable trans-1,2-cyclohexane bis(urea-urethane) compounds
US7144450B2 (en) * 2004-12-04 2006-12-05 Xerox Corporation Phase change inks containing trans-1,2-cyclohexane bis(urea-urethane) compounds
US7220300B2 (en) 2004-12-04 2007-05-22 Xerox Corporation Phase change inks containing bis(urea-urethane) compounds
US7314949B2 (en) 2004-12-04 2008-01-01 Xerox Corporation Trans-1,2-cyclohexane bis(urea-urethane) compounds
US7560587B2 (en) * 2004-12-04 2009-07-14 Xerox Corporation Bis[urea-urethane] compounds
JP5345073B2 (ja) * 2007-01-23 2013-11-20 テラピコン エス．アール．エル． 抗ウイルス化合物
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
CA2692417C (en) 2007-07-03 2017-03-21 Children's Hospital & Research Center At Oakland Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting
JP5597130B2 (ja) 2007-07-03 2014-10-01 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド ポリシアル酸脱ｎ−アセチラーゼの阻害剤及びその使用方法
CA2690440A1 (en) * 2007-07-03 2009-01-08 Children's Hospital & Research Center At Oakland Oligosialic acid derivatives, methods of manufacture, and immunological uses
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
EP2477985B1 (en) * 2009-09-15 2018-11-07 BlueLink Pharmaceuticals, Inc. Crlx101 for use in the treatment of cancer
IT1396620B1 (it) * 2009-11-25 2012-12-14 Therapicon Srl Analoghi chimerici
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
BR112013004275A2 (pt) * 2010-08-24 2016-08-02 Imp Innovations Ltd glicodendrímeros de polipropileterimina
CN104080450A (zh) * 2012-01-05 2014-10-01 阿拉维制药公司 扎那米韦生物利用度增强的制剂
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
CA2880701A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015109180A2 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI687428B (zh) 2014-03-27 2020-03-11 中央研究院 反應性標記化合物及其用途
JP7093612B2 (ja) 2014-05-27 2022-06-30 アカデミア シニカ Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
CN106573971A (zh) 2014-05-27 2017-04-19 中央研究院 抗cd20醣抗体及其用途
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7062361B2 (ja) 2014-05-27 2022-05-06 アカデミア シニカ 抗ｈｅｒ２糖操作抗体群およびその使用
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
AU2015315294B2 (en) 2014-09-08 2020-09-17 Academia Sinica Human iNKT cell activation using glycolipids
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
TWI736523B (zh) 2015-01-24 2021-08-21 中央研究院 新穎聚醣結合物及其使用方法
WO2017083914A1 (en) * 2015-11-20 2017-05-26 Australian Biomedical Co. Pty Ltd Compounds for medicinal applications
RU2612221C1 (ru) * 2015-12-16 2017-03-03 Общество с ограниченной ответственностью "Синтавр" Блокаторы вируса гриппа
JP2019515876A (ja) 2016-03-08 2019-06-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｎ−グリカンおよびそのアレイのモジュール合成のための方法
US10538592B2 (en) 2016-08-22 2020-01-21 Cho Pharma, Inc. Antibodies, binding fragments, and methods of use
CN108003065B (zh) * 2016-10-27 2021-01-08 中国石油化工股份有限公司 一种具有增稠作用的化合物和润滑脂以及它们的制备方法
WO2018199798A1 (ru) * 2017-04-28 2018-11-01 Общество с ограниченной ответственностью "Синтавр" Пептидные производные противовирусного препарата занамивира
US11773129B2 (en) * 2017-05-25 2023-10-03 The Governors Of The University Of Alberta Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase
CN111698999A (zh) * 2017-12-06 2020-09-22 阿道恰公司 包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的ph为7的可注射溶液
SG11202103313RA (en) 2018-09-06 2021-04-29 Cidara Therapeutics Inc Compositions and methods for the treatment of viral infections
SG11202102661UA (en) * 2018-10-05 2021-04-29 Univ Emory Monomer and multimeric anti-hbv agents
TW202122117A (zh) 2019-09-06 2021-06-16 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5243035A (en) * 1990-02-27 1993-09-07 Drug Delivery System Institute, Ltd. Sialic acid-containing glycolipid derivatives
EP0576592B1 (en) * 1991-03-18 2000-05-31 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
JPH07504222A (ja) * 1992-02-19 1995-05-11 ザ・バイオメンブレイン・インスティテュート 化学的に規定されるオリゴ糖，該オリゴ糖の誘導体，擬態物及び該オリゴ糖に対する抗体による細胞接着の抑制
JPH0638784A (ja) * 1992-03-30 1994-02-15 Meiji Milk Prod Co Ltd シアル酸を構成要素とする糖鎖の製造方法
ZA937034B (en) * 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
US5837689A (en) * 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5658880A (en) * 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
DE759917T1 (de) * 1995-02-27 1998-10-22 Gilead Sciences Inc Neue selektive inhibitoren viraler oder bakterieller neuraminidasen
US5780606A (en) * 1995-06-07 1998-07-14 Connaught Laboratories Limited Neisseria meningitidis capsular polysaccharide conjugates
IL125662A0 (en) 1996-03-01 1999-04-11 Biota Scient Management Method of detecting influenza virus and compounds for use therein
US5891862A (en) * 1996-03-15 1999-04-06 Geltex Pharmaceuticals, Inc. Polyvalent polymers for the treatment of rotavirus infection
AUPO104396A0 (en) 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Antiviral linear polymers
JP4179567B2 (ja) * 1996-07-23 2008-11-12 生化学工業株式会社 新規ラクトサミンオリゴ糖およびその製造方法
EA001603B1 (ru) 1996-11-14 2001-06-25 Байота Сайентифик Менеджмент Пти Лтд. Новые соединения и методы их применения
JPH10182686A (ja) * 1996-12-26 1998-07-07 Ngk Insulators Ltd ガングリオシドＧＱ１ｂ類縁物質
AU6852198A (en) 1997-04-17 1998-11-11 Fujimori Kogyo Co. Ltd. Chemical indicator sheets and packaging bags for sterilization made with the useof the same
CA2319495A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein

Also Published As

Publication number Publication date
CZ20013274A3 (cs) 2002-03-13
AU2896600A (en) 2000-10-04
ZA200107450B (en) 2002-09-10
NO20014409D0 (no) 2001-09-11
IL145346A0 (en) 2002-06-30
KR100805906B1 (ko) 2008-02-21
NO20014409L (no) 2001-11-01
JP5160000B2 (ja) 2013-03-13
TR200102794T2 (tr) 2002-09-23
NO327812B1 (no) 2009-09-28
TWI268279B (en) 2006-12-11
HUP0200190A2 (en) 2002-06-29
DE60020100T2 (de) 2006-01-19
ID29868A (id) 2001-10-18
BR0008939A (pt) 2001-12-18
HK1041693A1 (en) 2002-07-19
EP1165541A4 (en) 2002-06-05
PL350228A1 (en) 2002-11-18
WO2000055149A1 (en) 2000-09-21
HUP0200190A3 (en) 2004-01-28
CA2367755A1 (en) 2000-09-21
EP1165541B1 (en) 2005-05-11
EA200100968A1 (ru) 2002-02-28
CA2367755C (en) 2007-08-28
EP1165541A1 (en) 2002-01-02
KR20020005617A (ko) 2002-01-17
MXPA01009203A (es) 2002-08-20
NZ514041A (en) 2001-09-28
HK1041693B (zh) 2005-10-14
AU774222B2 (en) 2004-06-17
AP2001002277A0 (en) 2001-09-30
US6548476B1 (en) 2003-04-15
DE60020100D1 (de) 2005-06-16
CN1343205A (zh) 2002-04-03
JP2002539204A (ja) 2002-11-19
ES2241581T3 (es) 2005-11-01
ATE295361T1 (de) 2005-05-15
AUPP913999A0 (en) 1999-04-01

Similar Documents

Publication Publication Date Title
IL145346A (en) Dimeric compounds and their use as inhibitors of neuraminidase
IL149118A0 (en) Inhibitors of neuraminidases
HK1048247A1 (en) Stable carotene-xanthophyll beadlet compositions and methods of use
IL157659A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
HUP0105113A3 (en) Benzoheterocycles and their use as mek inhibitors and pharmaceutical compositions containing the compounds
NO20014858L (no) Anvendelse av CYP2D6 inhibitorer i kombinasjonsterapi
HUP0202251A3 (en) Heterocyclic containing biphenyl ap2 inhibitors and application
IL153246A0 (en) Substituted quinazoline derivatives and their use as inhibitors
IL145907A0 (en) Use of glucosylceramide synthesis inhibitors in therapy
HUP0200391A3 (en) Use of pharmaceutical compositions comprising dipeptidy peptidase iv inhibitors for the promotion of growth
HUP0004120A3 (en) Use of cgmp-pde5 inhibitors for the preparation of pharmaceutical compositions treating neuropathy
HUP0301005A3 (en) Pirrolotriazine inhibitors of kinases pharmaceutical compositions containing them and their use
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
HUP0300318A3 (en) Pyrazolobenzodiazepines as cdk2 inhibitors and pharmaceutical compositions containing them and their use
GB0025782D0 (en) Use of inhibitors
IL146000A0 (en) Ace-2 inhibiting compounds and methods of use thereof
ZA988469B (en) Pyrrolidin-2-one compounds and their use as neuraminidase inhibitors
HUP0201925A2 (en) Cyclic peptide derivatives as inhibitors of integrin alphavbeta6 and their use
PL352200A1 (en) Inhibitors of viia agent
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
IL131047A0 (en) Use of il-18 inhibitors
IL153328A0 (en) 2-aminothiazoline derivatives and their use as no-synthase inhibitors
AU7402201A (en) Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
AU7608100A (en) 1-cyclohexene-1-carboxylic acid and 1-cyclohexene-1-carboxylates as neuraminidase inhibitors
PL350963A1 (en) Use of arylalkanoylpyridazines

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees